PortfoliosLab logo
NVCR vs. EBS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NVCR and EBS is 0.80, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Performance

NVCR vs. EBS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NovoCure Limited (NVCR) and Emergent BioSolutions Inc. (EBS). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

NVCR:

87.23%

EBS:

319.66%

Max Drawdown

NVCR:

-8.05%

EBS:

-11.16%

Current Drawdown

NVCR:

-2.14%

EBS:

-11.16%

Fundamentals

Market Cap

NVCR:

$1.94B

EBS:

$307.00M

EPS

NVCR:

-$1.51

EBS:

-$3.60

PEG Ratio

NVCR:

-0.47

EBS:

1.55

PS Ratio

NVCR:

3.12

EBS:

0.29

PB Ratio

NVCR:

5.35

EBS:

0.64

Total Revenue (TTM)

NVCR:

$621.71M

EBS:

$737.80M

Gross Profit (TTM)

NVCR:

$479.70M

EBS:

$181.00M

EBITDA (TTM)

NVCR:

-$105.45M

EBS:

-$26.50M

Returns By Period


NVCR

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

EBS

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NVCR vs. EBS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVCR
The Risk-Adjusted Performance Rank of NVCR is 5959
Overall Rank
The Sharpe Ratio Rank of NVCR is 5757
Sharpe Ratio Rank
The Sortino Ratio Rank of NVCR is 6565
Sortino Ratio Rank
The Omega Ratio Rank of NVCR is 6161
Omega Ratio Rank
The Calmar Ratio Rank of NVCR is 5858
Calmar Ratio Rank
The Martin Ratio Rank of NVCR is 5757
Martin Ratio Rank

EBS
The Risk-Adjusted Performance Rank of EBS is 6767
Overall Rank
The Sharpe Ratio Rank of EBS is 6262
Sharpe Ratio Rank
The Sortino Ratio Rank of EBS is 7474
Sortino Ratio Rank
The Omega Ratio Rank of EBS is 7373
Omega Ratio Rank
The Calmar Ratio Rank of EBS is 6565
Calmar Ratio Rank
The Martin Ratio Rank of EBS is 6161
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NVCR vs. EBS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for NovoCure Limited (NVCR) and Emergent BioSolutions Inc. (EBS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

NVCR vs. EBS - Dividend Comparison

Neither NVCR nor EBS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NVCR vs. EBS - Drawdown Comparison

The maximum NVCR drawdown since its inception was -8.05%, smaller than the maximum EBS drawdown of -11.16%. Use the drawdown chart below to compare losses from any high point for NVCR and EBS. For additional features, visit the drawdowns tool.


Loading data...

Volatility

NVCR vs. EBS - Volatility Comparison


Loading data...

Financials

NVCR vs. EBS - Financials Comparison

This section allows you to compare key financial metrics between NovoCure Limited and Emergent BioSolutions Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M200.00M300.00M400.00M500.00M600.00M700.00M20212022202320242025
154.99M
189.30M
(NVCR) Total Revenue
(EBS) Total Revenue
Values in USD except per share items

NVCR vs. EBS - Profitability Comparison

The chart below illustrates the profitability comparison between NovoCure Limited and Emergent BioSolutions Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%20212022202320242025
75.2%
37.7%
(NVCR) Gross Margin
(EBS) Gross Margin
NVCR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, NovoCure Limited reported a gross profit of 116.47M and revenue of 154.99M. Therefore, the gross margin over that period was 75.2%.

EBS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported a gross profit of 71.30M and revenue of 189.30M. Therefore, the gross margin over that period was 37.7%.

NVCR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, NovoCure Limited reported an operating income of -37.87M and revenue of 154.99M, resulting in an operating margin of -24.4%.

EBS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported an operating income of -9.50M and revenue of 189.30M, resulting in an operating margin of -5.0%.

NVCR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, NovoCure Limited reported a net income of -34.32M and revenue of 154.99M, resulting in a net margin of -22.1%.

EBS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported a net income of -31.30M and revenue of 189.30M, resulting in a net margin of -16.5%.